Literature DB >> 33355217

Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.

Pan Luo1,2, Jian-Ling Zheng1,2, Yi Liu1, Lin Qiu1, Xiu-Lan Liu1, Hui-Ying Xue1, Dong Liu1,3, Juan Li4,3.   

Abstract

AIM: The inconsistent effects of lopinavir-ritonavir (LPV/r) on COVID-19 seem to be caused by the therapeutic window. In the present study, we aim to present the effects of early LPV/r treatment on patients with severe COVID-19.
METHODS: The demographics, characteristics, treatments, SARS-CoV-2 test results and outcomes of 19 patients with severe COVID-19 treated with LPV/r within 12 days of onset of symptoms were retrospectively assessed.
RESULTS: Within 3 days of admission, three (15.79%) patients received noninvasive ventilation, and 16 (84.21%) patients received high-flow oxygen support. The median duration between the onset of symptoms and initiating LPV/r therapy was 9 (range 2-12) days. The median course of LPV/r treatment was 11 (range 7-17) days. One of the 19 patients (5.26%) died. Of the 18 patients discharged, the median hospital stay was 17 (range 11-45) days. At day 6 after LPV/r therapy was initiated, 68.42% of patients were virologically cured, increasing to 84.22% at day 12.
CONCLUSION: In this cohort of patients with severe COVID-19 who were treated with LPV/r within 12 days of the onset of symptoms, clinical improvement was observed in 18/19 patients (94.74%). Randomised controlled trials are urgently needed to further evaluate this strategy. © Royal College of Physicians 2021. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; lopinavir–ritonavir

Year:  2020        PMID： 33355217      PMCID： PMC7850187          DOI： 10.7861/clinmed.2020-0348

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  16 in total

1.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.

Authors:  X-T Ye; Y-L Luo; S-C Xia; Q-F Sun; J-G Ding; Y Zhou; W Chen; X-F Wang; W-W Zhang; W-J Du; Z-W Ruan; L Hong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-03       Impact factor: 3.507

2.  Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.

Authors:  Pan Luo; Lin Qiu; Yi Liu; Xiu-Lan Liu; Jian-Ling Zheng; Hui-Ying Xue; Wen-Hua Liu; Dong Liu; Juan Li
Journal:  Am J Trop Med Hyg       Date:  2020-05-21       Impact factor: 2.345

3.  Compassionate Use of Remdesivir for Patients with Severe Covid-19.

Authors:  Jonathan Grein; Norio Ohmagari; Daniel Shin; George Diaz; Erika Asperges; Antonella Castagna; Torsten Feldt; Gary Green; Margaret L Green; François-Xavier Lescure; Emanuele Nicastri; Rentaro Oda; Kikuo Yo; Eugenia Quiros-Roldan; Alex Studemeister; John Redinski; Seema Ahmed; Jorge Bernett; Daniel Chelliah; Danny Chen; Shingo Chihara; Stuart H Cohen; Jennifer Cunningham; Antonella D'Arminio Monforte; Saad Ismail; Hideaki Kato; Giuseppe Lapadula; Erwan L'Her; Toshitaka Maeno; Sumit Majumder; Marco Massari; Marta Mora-Rillo; Yoshikazu Mutoh; Duc Nguyen; Ewa Verweij; Alexander Zoufaly; Anu O Osinusi; Adam DeZure; Yang Zhao; Lijie Zhong; Anand Chokkalingam; Emon Elboudwarej; Laura Telep; Leighann Timbs; Ilana Henne; Scott Sellers; Huyen Cao; Susanna K Tan; Lucinda Winterbourne; Polly Desai; Robertino Mera; Anuj Gaggar; Robert P Myers; Diana M Brainard; Richard Childs; Timothy Flanigan
Journal:  N Engl J Med       Date:  2020-04-10       Impact factor: 91.245

4.  Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.

Authors:  Elise Klement-Frutos; Sonia Burrel; Gilles Peytavin; Stéphane Marot; Minh P Lê; Nagisa Godefroy; Vincent Calvez; Anne-Geneviève Marcelin; Eric Caumes; Valérie Pourcher; David Boutolleau
Journal:  J Infect       Date:  2020-05-27       Impact factor: 6.072

5.  Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2020-10-05       Impact factor: 79.321

6.  Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression.

Authors:  Fang Liu; Aifang Xu; Yan Zhang; Weiling Xuan; Tingbo Yan; Kenv Pan; Wenyan Yu; Jun Zhang
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

7.  Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu.

Authors:  Yongli Zheng; Hong Xu; Ming Yang; Yilan Zeng; Hong Chen; Ru Liu; Qingfeng Li; Na Zhang; Dan Wang
Journal:  J Clin Virol       Date:  2020-04-10       Impact factor: 3.168

8.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

9.  Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression.

Authors:  Ian Huang; Michael Anthonius Lim; Raymond Pranata
Journal:  Diabetes Metab Syndr       Date:  2020-04-17

10.  Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.

Authors:  Periklis Panagopoulos; Vasilis Petrakis; Maria Panopoulou; Grigorios Trypsianis; Theano Penlioglou; Ioannis Pnevmatikos; Dimitrios Papazoglou
Journal:  J Chemother       Date:  2020-06-12       Impact factor: 1.714
View more
  1 in total

Review 1.  Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.

Authors:  Safaet Alam; Taslima Binte Kamal; Md Moklesur Rahman Sarker; Jin-Rong Zhou; S M Abdur Rahman; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-06-14       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.